ArticleMolecular biology reports2026
Association of EBV EBNA1 C-terminal variations with severity of Invasive ductal carcinoma.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a major cause of mortality, and Epstein-Barr virus (EBV) is considered a potential contributor to cancer development. EBV nuclear antigen 1 (EBNA1) plays a vital role in viral persistence. This study aimed to investigate the association among EBNA1 C-terminal variations and severity of invasive ductal carcinoma (IDC).
methodA total of 60 female participants, were included in this study. EBV positive biopsy samples (N = 30) were obtained from the breast cancer patients while 30 healthy females served as control. The C-terminal region of EBNA1 gene was amplified and sequenced. Statistical analysis was carried out using SPSS v25.
resultAmong the breast cancer patients, 97% had IDC and 3% had ductal carcinoma in situ. Regarding tumor grade, 3% of the patients had grade I, 63% had grade II and 33% had grade III tumors. The P-Thr (70%) and its co-infection with V-leu (30%) were observed predominantly in patients with higher grade; however, no significant association was observed. A total of 15 consensus single-nucleotide polymorphisms were observed along with six random mutations. No significant association was reported among random SNPs with breast cancer severity. Phylogenetic analysis shows that our sequences of P-Thr exhibited high similarity with reference sequence NC_009334. All control samples were EBV negative.
conclusionP-Thr was the predominant EBNA1 prototype in study population. However, no significant association was found between EBNA1 variations with breast cancer severity.
Indexed as
Identifiers
42667440What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.